Observed and expected rates of second neoplasms, according to type or site
| Type or site . | Observed/expected cases . | SIR (95% CI) . | Absolute risk per 104 y . |
|---|---|---|---|
| All cancers3-150 | 61/8.5 | 7.2 (5.5-9.1) | 9.6 |
| Leukemia | 16/0.3 | 59.4 (33.9-96.4) | 2.9 |
| AML/MDS3-151 | 14/0.3 | 52.3 (28.6-87.7) | 2.5 |
| Lymphoma | |||
| NHL3-152 | 5/0.6 | 8.3 (2.6-17.2) | 0.8 |
| Hodgkin disease | 2/0.7 | 2.7 (0.3-9.7) | 0.2 |
| Solid cancers3-153 | |||
| Brain tumors | 17/1.7 | 10.1 (5.9-16.2) | 2.8 |
| Soft tissue sarcoma | 4/0.4 | 9.1 (2.4-20.2) | 0.7 |
| Thyroid cancer | 4/0.3 | 13.3 (3.6-34.1) | 0.7 |
| Parotid gland tumors | 4/0.1 | 33.4 (9.1-85.6) | 0.7 |
| Type or site . | Observed/expected cases . | SIR (95% CI) . | Absolute risk per 104 y . |
|---|---|---|---|
| All cancers3-150 | 61/8.5 | 7.2 (5.5-9.1) | 9.6 |
| Leukemia | 16/0.3 | 59.4 (33.9-96.4) | 2.9 |
| AML/MDS3-151 | 14/0.3 | 52.3 (28.6-87.7) | 2.5 |
| Lymphoma | |||
| NHL3-152 | 5/0.6 | 8.3 (2.6-17.2) | 0.8 |
| Hodgkin disease | 2/0.7 | 2.7 (0.3-9.7) | 0.2 |
| Solid cancers3-153 | |||
| Brain tumors | 17/1.7 | 10.1 (5.9-16.2) | 2.8 |
| Soft tissue sarcoma | 4/0.4 | 9.1 (2.4-20.2) | 0.7 |
| Thyroid cancer | 4/0.3 | 13.3 (3.6-34.1) | 0.7 |
| Parotid gland tumors | 4/0.1 | 33.4 (9.1-85.6) | 0.7 |
Excludes 2 patients with meningioma.
Excludes the 2 patients with chronic leukemia.
Excludes 1 patient with Epstein-Barr virus–associated B-cell lymphoproliferative disease.
Excludes lymphatic and hematopoietic tumors. The sum of the solid tumors does not equal the total number given because only types for which the risk was significantly elevated were included.